Conatus Pharmaceuticals Inc (NASDAQ:CNAT) was the recipient of a large growth in short interest in January. As of March 14th, there was short interest totalling 985,400 shares, a growth of 82.6% from the February 28th total of 539,790 shares, Analyst Ratings News reports. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) stock performance was -6.33% in last session and finished the day at $7.10. Traded volume was 378,401.00million shares in the last session and the average volume of the stock remained 626.65K shares. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) insider ownership is 0.30%.

US-based biopharmaceutical company Kindred Biosciences Inc (NASDAQ:KIN) reported on Monday that it expects to launch USD50m shares of its common stock in a public offering. The company added the number of shares to be issued and the public offering price have not yet been determined. Kindred Biosciences Inc (NASDAQ:KIN) dropped -7.92 percent to $17.44 Monday on volume of 337,395.00million shares. The intra-day range of the stock was $17.23 to $19.06. Kindred Biosciences Inc (NASDAQ:KIN) has a market capitalization of $283.00million.

RUSNANO’s local investments include $35 million in Joule Unlimited of Bedford, which is developing renewable fuels, and $25 million in BIND Therapeutics Inc (NASDAQ:BIND), a biotech company in Cambridge cofounded by famed MIT scientist Robert Langer. BIND Therapeutics Inc (NASDAQ:BIND)’s stock on Apr 07, 2014 reported a decrease of -10.41% to the closing price of $9.73. Its fifty two weeks range is $8.36 -$15.89. The total market capitalization recorded $159.87million. The overall volume in the last trading session was 386,670.00million shares. In its share capital, BIND has 16.43million outstanding shares.

Many of the 180 million cats and dogs in the United States have moved from the wilds of the backyard to the warm and comfortable living quarters of their human owners. While this cushier existence is extending their lives, it also brings with it a higher risk of cancer and other diseases, according to Dr. Steven St. Peter, president and chief executive officer of Aratana Therapeutics Inc (NASDAQ:PETX). On Monday, shares of Aratana Therapeutics Inc (NASDAQ:PETX) dropped -11.74% to close the day at $15.33. Company return on investment (ROI) is -4.20% and its monthly performance is recorded as -25.47%. Aratana Therapeutics Inc (NASDAQ:PETX) quarterly revenue growth is -22.06%.